Fluxion Biosciences and Cellectricon AB Settle Patent Infringement Lawsuit

SOUTH SAN FRANCISCO, Calif. & MÖLNDAL, Sweden--(BUSINESS WIRE)--Cellectricon AB and Fluxion Biosciences today announced that they have settled the patent infringement litigation that Cellectricon commenced against Fluxion in 2009. Cellectricon and Fluxion have agreed to file a stipulation of dismissal with the United States District Court for the Northern District of California for all claims brought by Cellectricon against Fluxion for alleged infringement of Cellectricon’s U.S. Patent Nos. 7,390,650, 7,470,518, and 7,563,614. Under the terms of the settlement, Fluxion and Cellectricon will cross-license patents related to microfluidic cellular analysis. "We are very pleased to have achieved a successful conclusion to the litigation," said David A. Burns, Chief Executive Officer of Cellectricon. "Resolution of this lawsuit allows us to focus on providing innovative and enabling products and discovery services for drug discovery and life science research globally."